3-Methyl-4,5-tetramethylen-1,2,4-triazol | 118872-35-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并吡啶类
• 英文名称: 3-Methyl-4,5-tetramethylen-1,2,4-triazol
• 英文别名: 3-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine；3-Methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin；3-Methyl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine；3-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine
• CAS: 118872-35-8
• 化学式: C₇H₁₁N₃
• mdl: MFCD13176300
• 分子量: 137.184
• InChiKey: HGRDUWBMQIWTSB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.714
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  6-甲氧基-2,3,4,5-四氢吡啶 、 乙酰肼 在 甲醇 作用下， 生成 3-Methyl-4,5-tetramethylen-1,2,4-triazol
  参考文献：
  名称：

  Petersen; Tietze, Chemische Berichte, 1957, vol. 90, p. 909,818

  摘要：

  DOI：

文献信息

• [EN] NEW COMPOUNDS AND METHODS<br/>[FR] NOUVEAUX COMPOSÉS ET PROCÉDÉS
  申请人：BENEVOLENTAI BIO LTD

  公开号：WO2020260871A1

  公开（公告）日：2020-12-30

  The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof. The present invention also relates to pharmaceutical compositions comprising the compounds of the invention, and to their use in the treatment or prevention of medical conditions in which inhibition of c-ABL is beneficial. (I)

  本发明涉及式(I)的化合物或其药用可接受的盐、溶剂化合物、水合物、互变异构体、光学异构体、N-氧化物和/或前药。本发明还涉及包括本发明化合物的药物组合物，以及它们在治疗或预防抑制c-ABL有益的医疗状况中的使用。
• Multi-cyclic cinnamide derivatives
  申请人：Kimura Teiji

  公开号：US20070219181A1

  公开（公告）日：2007-09-20

  The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar 1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar 2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X 1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.

  本发明提供了一种由以下公式（I）表示的化合物或其药理学上可接受的盐，其中Ar1代表可能用C1-6烷基等取代的咪唑基团，Ar2代表可能用C1-6烷氧基等取代的苯基团，X1代表双键等，Het代表可能用C1-6烷基等取代的咪唑基团，该化合物对由Aβ引起的疾病具有治疗或预防作用。
• MULTI-CYCLIC CINNAMIDE DERIVATIVES
  申请人：KIMURA Teiji

  公开号：US20100168095A1

  公开（公告）日：2010-07-01

  The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.

  本发明提供了一种化合物，其化学式表示为(I)：或其药学上可接受的盐，其中Ar1代表可被C1-6烷基等取代的咪唑基团，Ar2代表可被C1-6烷氧基等取代的苯基团，X1代表双键等，Het代表可被C1-6烷基等取代的咪唑基团，该化合物对由Aβ引起的疾病具有治疗或预防作用。
• METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF
  申请人：Heffernan Michele L. R.

  公开号：US20140221332A1

  公开（公告）日：2014-08-07

  Compounds that modulate GluR5 activity and methods of using the same are disclosed.

  本发明揭示了调节GluR5活性的化合物及其使用方法。
• ASK1 inhibitor and preparation method and use thereof
  申请人：FUJIAN COSUNTER PHARMACEUTICAL CO., LTD.

  公开号：US10787435B2

  公开（公告）日：2020-09-29

  The present disclosure relates to a compound as shown in formula (II), a tautomer or a pharmaceutically acceptable salt thereof, and disclosed is the use thereof in preparing a drug for treating an ASK1-associated disease.

  本公开涉及一种如式（II）所示的化合物、其同系物或药学上可接受的盐，并公开了其在制备治疗 ASK1 相关疾病的药物中的用途。